ANALYSIS: The initial dopamine hit of expanding into a new market is often fleeting as reality bites and the realisation of what you bought sets in.
Delano GallagherTue, 24 Sep 2024
The story of Australian company CSL’s path from a government body focused on antivenoms, to the largest plasma provider globally is renowned.
CSL made a series of transformative acquisitions in the early-2000s, first Swiss-based ZLB for US$740 million and then US-based Aventis Behring for US$925m,
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
